Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acebrophylline is an airway mucus regulator with anti-inflammatory and bronchodilating properties. It is chemically a conjugate of ambroxol and theophylline-7-acetate. The theophylline component acts as a bronchodilator by inhibiting phosphodiesterase (PDE), which increases intracellular cAMP levels and leads to smooth muscle relaxation. The ambroxol component acts as a mucolytic by increasing surfactant production and reducing mucus viscosity, thereby facilitating expectoration. Additionally, acebrophylline inhibits the release of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting phospholipase A2. It is primarily indicated for the management of chronic obstructive pulmonary disease (COPD) and bronchial asthma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acebrophylline (Lucky's Pharma).